Cardiac biomarkers linked to future cancer risk, even without heart disease

Researchers at The University of Texas at Arlington have developed a new computational tool that helps scientists pinpoint proteins known as transcriptional regulators that control how genes turn on and off.

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.”

Three University of North Florida researchers recently received a second US patent for their cancer-fighting peptoid compound that can essentially “turn off” cancer. This new patent protects the compound based on its unique chemical structure, which mimics natural proteins in the body, but offers greater stability and a longer lifespan than traditional proteins.

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel pan-KRAS inhibitors of new chemotypes through structure-based drug design, scaffold hopping combined with intense molecular modeling, empowered by the generative chemistry methods of Chemistry42, Insilico’s proprietary generative chemistry platform. Developed in the joint efforts of artificial intelligence and human expertise, the candidate compounds demonstrated pan-KRAS inhibition with potency in the upper nanomolar range. The results have been recently published on ACS Medicinal Chemistry Letters.

Professor Marco Durante, Head of the Biophysics Department at GSI Helmholtzzentrum für Schwerionenforschung and Professor at the Department of Physics at TU Darmstadt, Institute of Condensed Matter Physics, has been granted a prestigious European Union research funding award for established scientists: The European Research Council (ERC) has awarded him the renowned Advanced Grant. The biophysicist will be able to use the millions in funding to realize an ambitious research project to improve tumor therapy. As lead scientist and together with his team he will conduct research into even more effective treatments for cancer and investigate a promising radiotherapy method that uses ultra-short pulses of heavy ion beams with ultra-high dose rates.